FDA Clears Way for Trials of FOR46 in Late-stage Multiple Myeloma, Prostate Cancer
The U.S. Food and Drug Administration has allowed Fortis Therapeutics’ antibody-drug conjugate FOR46 to begin testing in a Phase 1 clinical trial as a…
News
FDA Approves Empliciti Combination for Relapsed or Refractory Multiple Myeloma
The U.S. Food and Drug Administration has approved Bristol-Myers Squibb‘s Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, as a treatment…
Darzalex Add-on Delays Disease Progression or Death in Newly Diagnosed Multiple Myeloma, Phase 3 Trial Shows
Treatment with Darzalex (daratumumab) plus standard Revlimid (lenalidomide) and dexamethasone significantly delays the time to disease progression or death in newly diagnosed multiple myeloma…
Myeloma Crowd Launches Online Tool to Help Patients Find Treatment Options, Contribute to Research
Myeloma Crowd has launched an online tool called HealthTree, aimed at helping patients with multiple myeloma find the most appropriate therapies for their condition,…
New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study
A new investigational compound targeting a central pathway in cancer development showed promising results in patients with relapsed or refractory multiple myeloma…
Trip to Mount Everest’s Base Benefits MMRF-funded Multiple Myeloma Research
During a strenuous but spectacular hike, a team including four patients is traversing Nepal’s Khumbu region, encountering some of the world’s tallest mountains, and experiencing…
Revlimid Delays Disease Progression in Smoldering Myeloma Patients, Preliminary Trial Results Show
Celgene‘s immunomodulatory agent Revlimid (lenalidomide) significantly extended the time until disease progression in patients with smoldering multiple myeloma who were not yet experiencing any symptoms of…
Darzalex Add-on Increases Complete Responses After Stem Cell Transplant, Phase 3 Myeloma Trial Shows
Adding Darzalex (daratumumab) to the standard pre-transplant therapy for multiple myeloma significantly increased the number of patients showing no signs of cancer after…
STRO-001 Receives FDA’s Orphan Drug Status for Multiple Myeloma Treatment
STRO-001, Sutro Biopharma’s investigational therapy for multiple myeloma, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA). “There…
Selinexor Granted Priority Review by FDA for Heavily Treated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted priority review to Karyopharm Therapeutics’ application requesting accelerated approval of its investigational therapy selinexor as…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL